Sir, We read with great interest the report of a Tunisian family by [@aws049-B10] describing the neurological disorder linked to a novel heterozygous missense mutation in *MFN2* (1p36.2) ([@aws049-B10]). *MFN2* mutations typically cause autosomal dominant axonal Charcot--Marie--Tooth disease (CMT2A, OMIM 609260), with peripheral nerve degeneration occasionally associated with visual failure and optic atrophy ([@aws049-B15], [@aws049-B14]). Interestingly, the clinical manifestations among mutational carriers in this Tunisian family were even more variable, ranging from asymptomatic subclinical disease to an axonal sensorimotor neuropathy complicated by optic atrophy, deafness, cerebellar ataxia and proximal myopathy. Furthermore, the intriguing finding of cytochrome *c* oxidase (COX)-deficient fibres and multiple mitochondrial DNA deletions in skeletal muscle biopsies suggest that *MFN2* mutations can result in disturbed mitochondrial DNA maintenance and an overt respiratory chain defect, in addition to marked fragmentation of the mitochondrial network. These deleterious consequences are strikingly reminiscent of the pathological features recently highlighted in *Brain* for autosomal dominant optic atrophy due to *OPA1* mutations ([@aws049-B1]; [@aws049-B8]; [@aws049-B12]). Here, we provide additional evidence that *MFN2*-associated neuropathy is a novel disorder of mitochondrial DNA maintenance in a study of 58 probands with CMT2A and confirmed *MFN2* mutations ([Table 1](#aws049-T1){ref-type="table"}), compared with 131 age-matched normal controls. Table 1*MFN2* mutations identified in our patient cohortMutationTypeFunctional domainNumber of patientsp.Glu65StopNonsense--3p.Arg94TrpMissense--8p.Arg94GlnMissense--2p.Ala100GlyMissenseGTPase1p.Arg104LeuMissenseGTPase3p.Arg104TrpMissenseGTPase1p.Thr105AlaMissenseGTPase1p.His165TyrMissenseGTPase6p.Gly202AlaMissenseGTPase4p.Thr206IleMissenseGTPase2p.Thr232AsnMissenseGTPase1p.Arg250GlnMissenseGTPase1p.Arg259CysMissenseGTPase1p.Arg280HisMissenseGTPase1p.Gly298ArgMissenseGTPase1p.Glu308Stop[^a^](#aws049-TF1){ref-type="table-fn"}NonsenseGTPase1p.Arg364TrpMissenseCoiled-Coil 1 (CC1)1p.Arg364ProMissenseCoiled-Coil 1 (CC1)1p.Arg364GlnMissenseCoiled-Coil 1 (CC1)1p.Met376ValMissenseCoiled-Coil 1 (CC1)1p.Met376IleMissenseCoiled-Coil 1 (CC1)1p.Ala383ValMissenseCoiled-Coil 1 (CC1)1p.Arg468HisMissense--2p.Asp496GlyMissense--2p.Arg519Pro[^a^](#aws049-TF1){ref-type="table-fn"}Missense--1p.Leu673ProMissense--3p.Val705IleMissenseCoiled-Coil 2 (CC2)2p.Arg707TrpMissenseCoiled-Coil 2 (CC2)1p.Arg707ProMissenseCoiled-Coil 2 (CC2)1p.Ala716ThrMissenseCoiled-Coil 2 (CC2)1p.His750ProMissense--1p.Gln751StopNonsense--1p.Tyr752StopNonsense--1[^1]

Total genomic DNA was extracted from the leucocyte fraction of venous blood samples. The average cellular mitochondrial DNA content was quantified with a SYBR Green™ quantitative polymerase chain reaction assay on a MyiQ™ real-time polymerase chain reaction detection system (Biorad), with *MTND1* as the mitochondrial template and *GAPDH* as the nuclear-encoded housekeeping template ([@aws049-B12]). Relative mitochondrial DNA copy number was derived from the difference in threshold cycle (*C*~t~) values obtained for *MTND1* and *GAPDH* using the equation to account for two copies of *GAPDH* per cell nucleus.

Mitochondrial DNA levels in the *MFN2* group \[mean mitochondrial DNA copy number = 195.7, standard deviation (SD) = 126.6, *n* = 58\] were significantly higher compared with controls (mean mitochondrial DNA copy number = 60.9, SD = 42.3, *n* = 131, *P* \< 0.0001) ([Fig. 1](#aws049-F1){ref-type="fig"}A). Given the suggestion by [@aws049-B10] that *MFN2* mutations involving the functional GTPase domain were more likely to precipitate the severe multi-system phenotype documented in their family, we performed a subgroup analysis based on whether or not patients in our cohort harboured mutations within the highly conserved GTPase gene region. No significant difference was found between these two distinct mutational subgroups (*P* = 0.5957) ([Fig. 1](#aws049-F1){ref-type="fig"}B). Figure 1Comparison of mitochondrial DNA (MtDNA) blood copy number: (**A**) *MFN2* mutational carriers compared with age-matched normal controls; (**B**) patients harbouring *MFN2* mutations within the GTPase domain (mean mitochondrial DNA copy number = 207.9, SD = 150.2, *n* = *0 24*) compared with those located outside this region (mean mitochondrial DNA copy number = 189.8, SD = 108.2, *n* = 34); \*\*\**P* \< 0.0001; ns = not significant at *P* = 0.5957.

Although we have previously shown that variation in the differential blood cell count can affect blood-derived mitochondrial DNA copy number ([@aws049-B9]), the 3-fold increase in mitochondrial DNA content detected in our *MFN2* cohort was substantially greater than the error attributable to this possible confounding factor. Mitochondrial proliferation is a well-recognized important diagnostic feature in skeletal muscle of patients with a range of mitochondrial cytopathies ([@aws049-B11]; [@aws049-B2]). This compensatory mechanism is thought to occur in response to an underlying cellular bioenergetic crisis (the 'sick mitochondrion hypothesis'), which leads to the classical 'ragged-red fibre' appearance on Gomori Trichrome or succinate dehydrogenase staining ([@aws049-B5]; [@aws049-B3]; [@aws049-B6]). In this study, we have demonstrated the same phenomenon in blood leucocytes derived from patients with *MFN2* mutations. Although [@aws049-B10] determined mitochondrial DNA copy number in four skeletal muscle biopsies, they only report on the absence of mitochondrial DNA depletion in homogenate muscle extracts ([Table 1](#aws049-T1){ref-type="table"}). Pathologically increased mitochondrial DNA levels have been detected in laser-microdissected single skeletal muscle fibres from patients with *OPA1* mutations, this effect being particularly marked in COX-deficient muscle fibres ([@aws049-B13]). Given the overlapping clinical, histological and molecular characteristics observed in these two primary disorders of mitochondrial dynamics, it would be of great interest to know whether mitochondrial DNA proliferation was also present in muscle fibres from patients with *MFN2* mutations, especially in the two biopsies noted to have ragged-red fibres.

*MFN2* is the newest member of an expanding group of nuclear mitochondrial disorders characterized by disturbed mitochondrial DNA maintenance, a process which, increasingly, seems to be intrinsically related to the state of the mitochondrial network ([@aws049-B4]; [@aws049-B7]). Our observation that *MFN2* mutations cause mitochondrial proliferation in blood adds weight to the novel disease mechanism reported by [@aws049-B10]. Future work is needed to disentangle the complex interplay between disturbed mitochondrial fusion and fission, mitochondrial DNA instability and the eventual development of both neurological and visual deficits in patients with CMT2A and *MFN2* mutations.
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[^1]: ^a^One patient harboured two heterozygous *MFN2* mutations.
